Clinical trials: Dedifferentiated Liposarcoma
Dedifferentiated Liposarcoma
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause…
- Trial name
- MANTRA (NCT04979442)
- Testing
- RAIN-32, Trabectedin
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 175 people
- Sponsor
- Rain Oncology Inc
Liposarcoma, Dedifferentiated
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2.
- Trial name
- NCT06058793
- Testing
- Brigimadlin
- Where
- 56 sites in United States, Argentina and 5 more
- Volunteers
- 138 people
- Sponsor
- Boehringer Ingelheim
Liposarcoma, Dedifferentiated
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, in patients with…
- Trial name
- NCT05580588
- Testing
- SPH4336
- Where
- 9 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
Advanced Solid Tumors, Sarcoma
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1, open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum…
- Conditions
- Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT03604783
- Testing
- TP-1287
- Where
- 10 sites in United States
- Volunteers
- 74 people
- Sponsor
- Sumitomo Pharma America, Inc.
Dedifferentiated Liposarcoma
Selinexor in Advanced Liposarcoma
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma.
- Trial name
- SEAL (NCT02606461)
- Testing
- Selinexor
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 342 people
- Sponsor
- Karyopharm Therapeutics Inc
Advanced Solid Tumors
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
- Trial name
- NCT05944224
- Testing
- SPH4336, Cadonilimab
- Where
- 16 sites in China
- Volunteers
- 63 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Dedifferentiated Liposarcoma
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
- Trial name
- NCT00969917
- Testing
- IPI-504
- Where
- United States
- Sponsor
- Infinity Pharmaceuticals, Inc.
Dedifferentiated Liposarcoma
Real-world Study of Dedifferentiated Liposarcoma Patients in China
This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with…
- Trial name
- NCT06115681
- Where
- China
- Volunteers
- 1,390 people
- Sponsor
- Boehringer Ingelheim
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Liposarcoma, Dedifferentiated
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can participate.
- Trial name
- NCT05218499
- Testing
- Brigimadlin, Doxorubicin
- Where
- 109 sites in United States, Australia and 20 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
Sarcoma, Soft Tissue Sarcoma (STS)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
- Conditions
- Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
- Trial name
- 'SARATOGA' (NCT07741877)
- Testing
- Lifileucel
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Solid Tumor, Sarcoma
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell…
- Conditions
- Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06975293
- Testing
- STC-15 in combination with toripalimab, STC-15 monotherapy
- Where
- 14 sites in United States
- Volunteers
- 107 people
- Sponsor
- STORM Therapeutics LTD
Solid Tumor
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors.
- Trial name
- NCT06578624
- Testing
- SA53-OS (phase 1), SA53-OS (phase 2)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Lamassu Bio Inc
Dedifferentiated Liposarcoma
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.
- Trial name
- NCT05496569
- Testing
- TQB3616 capsule
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.